论文部分内容阅读
在90年代中期,首次对反应停在难治性多发性骨髓瘤患者治疗中的作用进行了评价。由于对这些患者的治疗取得了较好的效果,这种药物随后便应用于这种疾病早期阶段的治疗。同时,还发表了大量应用不同剂量的反应停治疗的临床Ⅱ期研究。为了增加反应停的有效性,在不同的背景下尝试了联合地塞米松、化疗和干扰素等方法。在这些试验中,也收集了有关反应停毒性作用方
For the first time in the mid-1990s, the role of response in the treatment of refractory multiple myeloma patients was evaluated. As a result of the better treatment of these patients, the drug is subsequently used in the early stages of the disease. At the same time, also published a large number of clinical application of different doses of response to clinical phase Ⅱ study. In order to increase the effectiveness of the response to stop in different contexts try to combine dexamethasone, chemotherapy and interferon and other methods. In these experiments, the side effects of the reaction to stop toxic also collected